# Healthy Tree

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/healthy-tree

- Industry: Medical Devices & Equipment
- Headquarters: Suzhou, China
- Website: www.healthytreemed.com
- Latest round: Series B (Mar 4, 2025)
- Investors on record: 10

## About

Suzhou Healthy Tree Medical Technology Co., Ltd is a company specializing in self-injection devices, focusing on innovative autoinjectors and injection solutions for pharmaceutical enterprises, enhancing patient-friendly medication delivery.Healthy Tree develops self-injection devices and was founded in 2018 in Suzhou, China. The company has engaged in 1 deal to date with the most recent deal occurring on March 4, 2025. The founder’s background information is currently not available.Suzhou Healthy Tree Medical Technology Co., Ltd specializes in the development and provision of self-injection devices, specifically focusing on autoinjectors and associated injection solutions tailored for pharmaceutical enterprises. Their core offerings include pen-type injectors, safety protection devices, and biopharmaceutical supporting equipment, all designed to enhance the safety and efficacy of drug administration. These products aim to address the growing demand for patient-friendly medication delivery systems, ensuring ease of use for individuals self-administering treatments. The company serves a diverse client base, including pharmaceutical firms and healthcare providers, operating primarily in international markets such as North America and Europe, where there is a significant push for innovative healthcare solutions. By providing comprehensive self-injection system solutions, the company positions itself as a leader in the self-administration device sector.The revenue structure of Suzhou Healthy Tree Medical Technology Co., Ltd is primarily driven by direct business-to-business transactions with pharmaceutical companies and healthcare organizations. Through partnerships and collaborations, the company engages in the supply of its self-injection devices and solutions, facilitating recurring revenue streams from ongoing contracts and product sales. The transaction model is centered around bulk orders or long-term agreements, ensuring a steady flow of income as clients rely on the company for their injection device needs. While specific pricing details for individual products or services are not disclosed, the company’s flagship products, including their proprietary autoinjectors and related safety devices, play a crucial role in their revenue generation strategy, as they cater to the increasing demand for reliable and user-friendly drug delivery systems.In March 2025, Suzhou Healthy Tree Medical Technology Co., Ltd raised an undisclosed amount in Series B funding jointly led by new investors GL Ventures and Hongshi Houfeng Investment, with participation from Trinity Innovation Fund and Zhengwei Capital, along with returning investors Innovent Biologics, Inc. and Triwise Capital. The funding will be utilized for the development of self-administration drug delivery devices (autoinjectors), automation of production lines, and expansion into global markets. The company plans to introduce new products designed for improved self-injection capabilities, while also targeting expansion into regions beyond its current markets, specifically aiming at further penetration of North America and Europe by the end of 2025.

## Funding rounds

- Series B, Mar 4, 2025 — CLSA Capital Partners, Innovent Biologics, Inc., Triwise Capital, GL Ventures, Trinity Innovation Fund, Zhengwei Capital, Hongshi Houfeng Investment
- Series A, Dec 8, 2022 — Addor Capital, Sherpa Healthcare Partners, Suzhou Xincheng Private Equity Fund Management

## Investors

- Addor Capital (https://capitalatlas.ai/funds/addor-capital) — Series A
- Sherpa Healthcare Partners (https://capitalatlas.ai/funds/sherpa-healthcare-partners) — Series A
- Suzhou Xincheng Private Equity Fund Management (https://capitalatlas.ai/funds/suzhou-xincheng-private-equity-fund-management) — Series A
- CLSA Capital Partners (https://capitalatlas.ai/funds/clsa-capital-partners) — Series B
- Innovent Biologics, Inc. — Series B
- Triwise Capital (https://capitalatlas.ai/funds/triwise-capital) — Series B
- GL Ventures (https://capitalatlas.ai/funds/gl-ventures) — Series B
- Trinity Innovation Fund (https://capitalatlas.ai/funds/trinity-innovation-fund) — Series B
- Zhengwei Capital — Series B
- Hongshi Houfeng Investment — Series B